https://www.benzinga.com/pressreleases/22/12/n30198813/harm-reduction-therapeutics-new-drug-application-for-rivive-over-the-counter-naloxone-nasal-spray-
0
0
Harm Reduction Therapeutics' New Drug Application for RiVive™ Over-the-Counter Naloxone Nasal Spray Accep - Benzinga
12/26/22 at 4:22pm
Organization
Benzinga
Author
PRNewswire
Details
48 words
Summarize
Drugs & Medications Sensitive Subjects Health New Drug Application Harm Reduction Therapeutics over-the-counter naloxone nasal spray advances RiViveTM Over-the-Counter FDA Pittsburgh emergency treatment PRNewswire
Low-cost, over-the-counter naloxone nasal spray advances to FDA review. Approval would increase access to this lifesaving medicine for the emergency treatment of opioid overdose. PITTSBURGH, Dec. 26, 2022 /PRNewswire/ --
Create an account or login to join the discussion